Article Versions Notes

Yamasaki S, Iida H, Saito A, Matsumoto M, Kuroda Y, Izumi T, Saito AM, Miyoshi H, Ohshima K, Nagai H, et al. Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma. Hematology Reports. 2024; 16(2):336-346. https://doi.org/10.3390/hematolrep16020034

Yamasaki, Satoshi, Hiroatsu Iida, Akio Saito, Morio Matsumoto, Yoshiaki Kuroda, Tohru Izumi, Akiko M. Saito, Hiroaki Miyoshi, Koichi Ohshima, Hirokazu Nagai, and et al. 2024. "Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma" Hematology Reports 16, no. 2: 336-346. https://doi.org/10.3390/hematolrep16020034

Yamasaki, S., Iida, H., Saito, A., Matsumoto, M., Kuroda, Y., Izumi, T., Saito, A. M., Miyoshi, H., Ohshima, K., Nagai, H., & Iwasaki, H. (2024). Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma. Hematology Reports, 16(2), 336-346. https://doi.org/10.3390/hematolrep16020034